合富中国(603122) - 2025 Q2 - 季度业绩预告

Current Period Performance Forecast The company anticipates a loss for the first half of 2025, with net profit attributable to owners of the parent company projected to be between -9.0 million RMB and -6.3 million RMB Estimated Performance Indicators | Performance Indicators | Estimated Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Owners of the Parent Company | -9.0 million to -6.3 million | | Net Profit Attributable to Owners of the Parent Company After Deducting Non-Recurring Gains and Losses | -8.72 million to -6.02 million | Prior Period Operating Performance and Financial Position Contrary to the current period's projected loss, the company achieved profitability in the prior period (first half of 2024), with net profit attributable to owners of the parent company at 22.5219 million RMB Prior Period Performance Indicators | Performance Indicators | Amount (RMB) | | :--- | :--- | | Total Profit | 31.2322 million | | Net Profit Attributable to Owners of the Parent Company | 22.5219 million | | Net Profit Attributable to Owners of the Parent Company After Deducting Non-Recurring Gains and Losses | 20.7641 million | | Earnings Per Share | 0.06 RMB/share | Primary Reasons for Current Period's Projected Loss The current period's projected loss is primarily due to declining sales revenue and gross profit, increased R&D and market investment, exchange losses, and a slower reduction in expenses - Sales revenue and gross profit simultaneously declined due to the domestic macroeconomic environment and policies such as centralized procurement price reductions, leading to lower hospital client purchase prices and reduced order volumes[8] - To adapt to market changes, the company adjusted its business layout, continuously investing resources in the iterative R&D, production, and market development of its proprietary "ACME" product[8] - The appreciation of the New Taiwan Dollar resulted in exchange losses for the company, negatively impacting net profit[8] - Despite implementing expense controls, the short-term decrease in administrative and selling expenses was less than the reduction in revenue, contributing to the performance decline[8] Risk Warning and Other Disclosures The company explicitly states that this performance forecast data is a preliminary calculation and has not been audited, with the final accurate financial data to be released in the official 2025 semi-annual report - This performance forecast has not been audited by a certified public accountant, and the final accurate data will be based on the company's officially disclosed 2025 semi-annual report[9][10]